106 related articles for article (PubMed ID: 19408743)
1. [Genomics arrives to the clinical practices in colorectal cancer].
Jankilevich G
Acta Gastroenterol Latinoam; 2009 Mar; 39(1):81-4. PubMed ID: 19408743
[No Abstract] [Full Text] [Related]
2. K-Ras mutations are changing practice in advanced colorectal cancer.
McNeil C
J Natl Cancer Inst; 2008 Dec; 100(23):1667-9. PubMed ID: 19033564
[No Abstract] [Full Text] [Related]
3. Targeting EGFR in colorectal cancer.
Messersmith WA; Ahnen DJ
N Engl J Med; 2008 Oct; 359(17):1834-6. PubMed ID: 18946069
[No Abstract] [Full Text] [Related]
4. K-ras mutations and cetuximab in colorectal cancer.
De Roock W; Lambrechts D; Tejpar S
N Engl J Med; 2009 Feb; 360(8):834; author reply 835-6. PubMed ID: 19238676
[No Abstract] [Full Text] [Related]
5. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
Zhang W; Labonte MJ; Lenz HJ
Ann Oncol; 2011 Feb; 22(2):484-5. PubMed ID: 21278223
[No Abstract] [Full Text] [Related]
6. K-ras mutations and cetuximab in colorectal cancer.
Codacci-Pisanelli G; Spinelli G; Tomao S
N Engl J Med; 2009 Feb; 360(8):835; author reply 835-6. PubMed ID: 19238679
[No Abstract] [Full Text] [Related]
7. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
Garassino MC; Farina G; Rossi A; Martelli O; Torri V
J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
[No Abstract] [Full Text] [Related]
8. KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.
Lenz HJ; Chu E; Grothey A
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-13, 14-6. PubMed ID: 19378369
[TBL] [Abstract][Full Text] [Related]
9. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
[No Abstract] [Full Text] [Related]
10. [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].
Ariyama H; Kusaba H; Baba E
Gan To Kagaku Ryoho; 2010 May; 37(5):782-6. PubMed ID: 20495306
[TBL] [Abstract][Full Text] [Related]
11. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients.
Ruzzo A; Canestrari E; Galluccio N; Santini D; Vincenzi B; Tonini G; Magnani M; Graziano F
Ann Oncol; 2011 Jan; 22(1):234-235. PubMed ID: 20926546
[No Abstract] [Full Text] [Related]
12. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
13. Cetuximab for metastatic colorectal cancer.
Sharma SP
Lancet Oncol; 2007 Aug; 8(8):673. PubMed ID: 17726778
[No Abstract] [Full Text] [Related]
14. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
15. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab in metastatic colorectal cancer.
Wolf I; Golan T; Shani A; Aderka D
Lancet Oncol; 2010 Apr; 11(4):313-4; author reply 314. PubMed ID: 20359660
[No Abstract] [Full Text] [Related]
17. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of using cetuximab and bevacizumab in a patient with colorectal cancer and terminal renal failure.
Inauen R; Cathomas R; Boehm T; Koeberle D; Pestalozzi BC; Gillessen S; von Moos R
Oncology; 2007; 72(3-4):209-10. PubMed ID: 18160810
[No Abstract] [Full Text] [Related]
20. [Consensus and dispute in histopathology of gastrointestinal tract].
Lai MD; Teng XD; Xu FY
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):289-91. PubMed ID: 21756819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
